Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) - Concepedia

Concepedia

Publication | Open Access

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

DOI Full Paper Access

322

Citations

34

References

2022

Year

Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal, Amelia Insa, M.R. García-Campelo, J. Casal Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí,

Journal of Clinical Oncology

Abstract

The efficacy of neoadjuvant chemotherapy plus nivolumab in resectable NSCLC is supported by 3-year OS. ctDNA levels were significantly associated with OS and outperformed radiologic assessments in the prediction of survival.

References

	Year	Citations

Page 1